Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.
about
Intelligent design: combination therapy with oncolytic virusesAdapting the Stress Response: Viral Subversion of the mTOR Signaling PathwayStress Beyond Translation: Poxviruses and MoreSerotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus.Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virusOncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic virusesA bioactive peptide analogue for myxoma virus protein with a targeted cytotoxicity for human skin cancer in vitroThe battle over mTOR: an emerging theatre in host-pathogen immunityA whole-genome RNA interference screen for human cell factors affecting myxoma virus replicationGene therapy progress and prospects cancer: oncolytic viruses.Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replicationMyxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cellsMyxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbitsMyxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer.Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycinOncolytic herpes viruses, chemotherapeutics, and other cancer drugsPI3K signaling regulates rapamycin-insensitive translation initiation complex formation in vaccinia virus-infected cells.Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded.Pharmacologic and chemical adjuvants in tumor virotherapy.The current status and future directions of myxoma virus, a master in immune evasion.Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Tinkering with translation: protein synthesis in virus-infected cells.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Virotherapy in cancerOncolytic virotherapy for urological cancers.Investigation of cytotoxicity of negative control peptides versus bioactive peptides on skin cancer and normal cells: a comparative study.Pharmacological manipulation of the akt signaling pathway regulates myxoma virus replication and tropism in human cancer cells.Differential susceptibility of human cancer cell lines to wild-type tanapoxvirus infection.Myxoma virus: propagation, purification, quantification, and storageMyxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits.Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors.Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells.
P2860
Q24628227-DC279C58-D25B-4E47-AB96-D69283DAB4ABQ26700049-66C2FAD9-1918-4256-B43B-F88AD170A2BCQ26744471-ABAFCF40-53B0-4C87-B9BD-5951AD9E6EEFQ32183285-8EA9FBAD-3C99-4547-B97F-0BAD9B6009A7Q33750535-62E878FB-8BD3-482D-ACD1-1DA193F4819DQ33895494-D1F991F5-2070-4750-8894-CA21E925B59AQ33924550-A5FEBAA5-6A5F-484A-8772-47F1C7A29C9FQ34340401-2BA0AC51-B6E3-485B-802D-D185A5775BF6Q34426431-1F534220-B7FD-4EBD-B8B2-CE348BEEC931Q34585582-289ED78E-3E08-4ED5-A663-62AFDD1ED1F9Q34770611-E14E981C-CFF9-4AF3-A4A5-BECE98478507Q34770719-216C513C-63D0-427F-8D07-EB812D5BC0A1Q35097829-D85BEB7C-D9C3-4795-B1D1-65D7B058F703Q35216344-E1E34F17-2C4C-4E42-BDF2-744DA16F10F6Q35223458-4AFFD258-CC0E-450B-BAC0-EB6EF9D7D909Q35234447-725DBBB3-2FC8-4D3C-A951-21CE6AE4FD4AQ35545752-3C8C0526-BFE3-41B9-A927-5DC1650BA15BQ35876172-3A242BB8-032A-4A23-B7F9-CF6FF593ADE5Q36315458-290D182D-FC8A-4333-B1B5-34D96602DD06Q36922264-42783799-6D11-42B7-B4E1-EB198D69D888Q36943893-4EE5EF82-91A7-475B-B4BF-2F5C4BBBDFFEQ37031896-2A3EB968-22C6-47F8-AF1A-968E2A9E27F3Q37145278-028F59CA-13E5-4AB9-BE81-10A612C54C25Q37191007-15F31608-498F-43E3-A391-F3C366D790CBQ37492540-08BCE0B5-FBFF-49FE-82EB-4E156DFF3611Q37887080-E2949108-958C-431C-91B4-EADD8506A30BQ37899223-BFD5A9CB-4BEE-48E3-8703-09A86C4DF1D9Q38025696-0F4E03E0-84F6-477F-9F50-145FB8B67C0EQ38064834-23AF906B-8119-47E4-8396-1C883596AB88Q38223419-6D4F9B85-ABC5-44E0-AA07-FD0D4048726BQ38237657-663DF381-BEA3-4F38-A06E-E45B5B6E668DQ38253646-6AFAA88A-3677-4B18-A917-A02C3D7C81BAQ38842126-FF7EDC98-C5D2-4578-BF11-0C9C6D81EA2DQ39292187-B030A9A6-205D-45D1-94D5-FC7FE1780B60Q39610261-07963935-F93A-4D95-840C-D44E2CBBBFF3Q39704822-7E9FF15E-863A-4C12-8F75-0EF9977427A1Q39707862-3E01E69C-EA24-429C-9764-6E453EB46245Q39995833-CD6AE14B-7A10-454F-A607-8D5E0551DA94Q42118566-6051D120-8253-421E-9B11-A859C91A0E79Q44837303-1BA52436-D3E1-4078-A604-DA21B7EB44E6
P2860
Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Oncolytic virotherapy synergis ...... tropism for human tumor cells.
@ast
Oncolytic virotherapy synergis ...... tropism for human tumor cells.
@en
type
label
Oncolytic virotherapy synergis ...... tropism for human tumor cells.
@ast
Oncolytic virotherapy synergis ...... tropism for human tumor cells.
@en
prefLabel
Oncolytic virotherapy synergis ...... tropism for human tumor cells.
@ast
Oncolytic virotherapy synergis ...... tropism for human tumor cells.
@en
P2093
P2860
P356
P1433
P1476
Oncolytic virotherapy synergis ...... tropism for human tumor cells.
@en
P2093
John W Barrett
Marianne M Stanford
Steven H Nazarian
Steven Werden
P2860
P304
P356
10.1128/JVI.01408-06
P407
P577
2006-11-15T00:00:00Z